Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.

Cervical Intraepithelial Neoplasia 3 Clinical Trial

Official title:
A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3.

Status Recruiting

Clinical Trial Summary

This is a study to investigate the safety and efficacy of GX-188E administered IM plus local administration of GX-I7 or Imiquimod at cervix in subjects with cervical intraepithelial neoplasia (CIN) 3.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03206138
Study type	Interventional
Source	Seoul St. Mary's Hospital
Contact	Jong-Sup Park
Phone	+82-2-2258-2724
Email	jspark@catholic.ac.kr
Status	Recruiting
Phase	N/A
Start date	May 30, 2017
Completion date	October 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01634503` - Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3	Phase 1
Active, not recruiting	`NCT02411019` - Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation	N/A
Recruiting	`NCT03958240` - Deciphering Mechanisms Underlying Cancer Immunogenicity	N/A
Active, not recruiting	`NCT02100085` - Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation	N/A